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Abstract 
Background: Thoracic aortic aneurysms and dissections (TAAD) are silent but possibly lethal condition with up to 
40 % of cases being hereditary. Genetic background is heterogeneous. Recently next‑generation sequencing enabled 
efficient and cost‑effective examination of gene panels. Aim of the study was to define the diagnostic yield of NGS in 
the 51 TAAD patients and to look for genotype–phenotype correlations within families of the patients with TAAD.
Methods: 51 unrelated TAAD patients were examined by either whole exome sequencing or TruSight One sequenc‑
ing panel. We analyzed rare variants in 10 established thoracic aortic aneurysms‑associated genes. Whenever possible, 
we looked for co‑segregation in the families. Kaplan–Meier survival curve was constructed to compare the event‑free 
survival depending on genotype. Aortic events were defined as acute aortic dissection or first planned aortic surgery.
Results and discussion: In 21 TAAD patients we found 22 rare variants, 6 (27.3 %) of these were previously reported, 
and 16 (73.7 %) were novel. Based on segregation data, functional analysis and software estimations we assumed that 
three of novel variants were causative, nine likely causative. Remaining four were classified as of unknown significance 
(2) and likely benign (2). In all, 9 (17.6 %) of 51 probands had a positive result when considering variants classified as 
causative only and 18 (35.3 %) if likely causative were also included. Genotype‑positive probands (n = 18) showed 
shorter mean event free survival (41 years, CI 35–46) than reference group, i.e. those (n = 29) without any plausible 
variant identified (51 years, CI 45–57, p = 0.0083). This effect was also found when the ‘genotype‑positive’ group was 
restricted to probands with ‘likely causative’ variants (p = 0.0092) which further supports pathogenicity of these vari‑
ants. The mean event free survival was particularly low (37 years, CI 27–47) among the probands with defects in the 
TGF beta signaling (p = 0.0033 vs. the reference group).
Conclusions: This study broadens the spectrum of genetic background of thoracic aneurysms and dissections and 
supports its potential role as a prognostic factor in the patients with the disease.
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Background
Thoracic aortic aneurysms (TAA) are a significant cause 
of morbidity and mortality. The actual incidence is hard 
to estimate as the disease usually remains silent until an 
acute aortic dissection (AAD) or rupture occurs. Inci-
dence of AAD is assessed at 2–3.5/100,000 inhabitants/
year in the US [1]. It is also evaluated that individual life-
time risk of rupture or dissection reaches 34  % by the 
time aorta achieves a diameter of 6 cm [2].
There are two major types of TAAs: sporadic 
(degenerative/atherosclerotic) and hereditary thoracic 
aortic aneurysms and dissections (TAAD). Familial 
form is found in 20–40 % of TAAD cases when at least 
two subjects within single family are diagnosed with 
TAAD [3, 4]. TAAD may be a part of well-character-
ized genetic syndromes such as Marfan syndrome 
(MFS), Loeys–Dietz syndrome (LDS), vascular type 
of Ehlers–Danlos syndrome (EDS), Shprintzen–Gold-
berg syndrome—all named syndromic TAAD. How-
ever most TAAD patients do not meet the criteria of 
those syndromes and are defined as as non-syndromic 
TAAD [5].
After the discovery of the defect in fibrillin 1 gene 
(FBN1) as the mechanism underlying pathogenesis 
of MFS, and the identification of first causative muta-
tion in 1991 [6–8], there are currently over 1300 muta-
tions in HGMD database referred to MFS and over 
3000 entries in UMD-FBN1 mutations database (http://
www.umd.be/FBN1/). In 2003 Kroes et  al. [9] related 
EDS to mutations in COL3A1, the following year Miz-
uguchi et  al. [10] associated TGFBR2 mutations with 
marfanoid phenotype, and finally in 2005 Loeys and 
colleagues distinguished and characterized LDS as the 
separate entity caused by defects in the TGFBR1 and 
TGFBR2 genes [11]. Soon followed the discoveries of 
genes responsible for non-syndromic TAAD [12, 13]. 
Autosomal dominant transmission of the TAAD has 
been proven in vast majority of patients with the dis-
ease, although in some probands with healthy parents, 
de novo mutations occur.
Introduction of next-generation sequencing (NGS) 
enabled efficient and cost-effective examination of all 
coding genes (whole exome sequencing, WES) or chosen 
gene panels.
Aim of the study was to define the diagnostic yield of 
NGS in 51 TAAD patients, to search for novel mutations 
in TAAD-associated genes, as well as genotype-pheno-
type correlations within families of TAAD patients.
Methods
Patients and consent
The study cohort was chosen from all index patients 
referred with the diagnosis of TAAD for clinical genetic 
testing from 2012 to 2014 to the Unit for Screening Stud-
ies in Inherited Cardiovascular Diseases, Institute of 
Cardiology and comprised 51 unrelated patients and 64 
relatives of genotype positive patients. Patients with fam-
ily history of aortic disease, early onset of aortic disease, 
suspected connective tissue disorders were included pri-
mary. In all patients a three-to-four generation pedigree 
was drawn and the data on the presence of TAAD, and 
other diseases in the family were collected. Every effort 
was made to review medical data on deceased subjects 
to confirm familial form of TAAD. For patients sus-
pected of MFS and their relatives revised Ghent criteria 
were used [14] and a detailed questionnaire was applied 
to define the involvement of other systems and organs. 
Systemic score for each patient was calculated with web 
calculator http://www.marfan.org/resources/profession-
als/marfandx. In addition, web questionnaires were used 
to assess systemic features of LDS http://www.loeysdi-
etz.org/ and Sphrintzen–Goldberg syndrome [15]. With 
regard to cardiovascular system, all patients had Dop-
pler echocardiographic study and CT scan of the entire 
aorta. In particular, we collected the following data: age 
at diagnosis of all features, namely of the presence of 
TAA, the history of AAD, the presence of aortic arch and 
descending aorta dissection, the prophylactic surgery 
for thoracic aorta surgery (aortic root, ascending aorta). 
Indications for planned surgery relied on available guide-
lines and evolved with time. Definition of aortic root 
dilatation and ascending aorta dilatation were based on 
echocardiography with calculation of Z-score for aor-
tic root using Web calculator http://www.marfan.org/
resources/professionals/marfandx. According to guide-
lines, patients were followed-up with serial examina-
tions by two-dimensional echocardiography and/or CT 
scan of the aorta. Both acute aortic dissection and first 
planned aortic surgery were considered aortic events. 
Data concerning mitral valve included presence of mitral 
valve prolapse (MVP) and mitral regurgitation (MR) on 
echocardiography. Diagnosis for MVP was based upon 
published criteria [16]. Familial disease was defined as 
the presence of >1 patient with TAAD in the family. This 
study was approved by the Bioethics Committee in the 
Institute of Cardiology (ref. no. 1273). All participants 
of the study gave an informed written consent including 
Keywords: Thoracic aortic aneurysm and dissections, Next‑generation sequencing, Diagnosis, Marfan syndrome, 
Loeys–Dietz syndrome, Shprintzen–Goldberg syndrome
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specific consent to genetic testing and permission to pub-
lish the results.
Genetic testing
DNA was extracted from the peripheral blood by stand-
ard salting out method and from buccal swab using Max-
well® 16 instrument with DNA IQ™ Casework Pro Kit 
(Promega).
In all probands sequencing was performed on 
HiSeq  1500. In 29 patients whole exome sequencing 
(WES) was performed, and in 22 TruSight One (TSO) 
sequencing panel (Illumina, San Diego, CA, USA) was 
used. WES sequencing libraries were prepared using 
TruSeq Exome Enrichment Kit (Illumina, San Diego, CA, 
USA) or Nextera Rapid Capture Exome (Illumina, San 
Diego, CA, USA) as described previously  [17].
We considered variants located in the coding or splic-
ing regions of one of established TAAD genes with 
autosomal dominant transmission pattern (Table  1), 
of frequency no greater than 0.001 in all of three data-
bases (1000Genomes, ESP and ExAC). Mutation was 
considered novel when absent from HGMD database 
(release 2015.1). To assess pathogenicity of novel vari-
ants we used algorithms supplied by ANNOVAR soft-
ware (http://annovar.openbioinformatics.org/en/latest/
user-guide/filter/#-lrt-annotation). Thus identified vari-
ants were followed-up with Sanger sequencing using 
a 3130xL Genetic Analyzer (Applied Biosystems, Fos-
ter City, CA, USA) and BigDye Terminator v1.1 Cycle 
Sequencing Kit (Applied Biosystems) according to the 
manufacturer’s instructions. The results were analyzed 
with Mutation Surveyor 3.30 Software (SoftGenetics). 
List of primers specific to each variant is available in 
Additional file  1. Amplification and Sanger sequencing 
of the beginning of exon 1 of SKI because of its CG-rich 
content was based on modification of methods pub-
lished by Naz and Fatima [18]. Details are available in 
Additional file 1.
Once mutation was identified, screening was offered 
to consenting relatives. Whenever possible we looked for 
co-segregation in the TAAD families.
Statistical analysis
All results for categorical variables were presented as 
numbers and percentages and for continuous variables 
as mean and standard deviation (SD). Kaplan–Meier sur-
vival curves were used to compare event-free survival 
between genotype positive and negative patients. All tests 
were two-sided with the significance level of p  <  0.05. 
Calculations were performed with SPSS package.
Results and discussion
Clinical findings
Table  2 shows summarized clinical characteristics of the 
study group. Mean age at the time of genetic inquest in the 
study group was 44 ± 13.8 years and 35 (68.6 %) patients 
were male. More than two-thirds of TAAD patients 
(n = 36, 70.6 %) had aortic events. Namely in 17 (33.3 %) 
patients AAD was first symptom of the disease at mean age 
of 40.1 years, and 19 (37.3 %) had planned aortic surgery 
at mean age of 44 years as first procedure. The remaining 












Table 2 Clinical characteristics of the study group, n = 51
Clinical characteristics of the study group
Age at the genetic inquest (mean ± SD, years) 44.8 ± 13.8
Male sex (n, %) 35 (68.6)
AAD (n,  %) 17 (33.3)
Age at AAD (mean ± SD, years) 40.1 ± 13.0
Planned TAA surgery (n, %) 25 (49)
Age at planned TAA surgery (mean ± SD, years) 42.2 ± 17
Planned TAA surgery—first procedure in the patient (n, %) 19 (37.3)
Age at the planned TAA surgery‑ first procedure in the  
patient (mean ± SD, years)
44 ± 16.8
TAA with no criteria for surgery (n, %) 15 (29.4)
Age at last examination (mean ± SD, years) 39.9 ± 14.9
Suspected MFS (n, %) 13 (25.5)
Familial TAAD 25 (49)
Associated structural abnormalities (n, %)
BAV 11 (21.6)
CoA + BAV 1 (1.9)
ASD and LVNC 1 (1.9)
Other CV diseases (n, %)
Stroke 3 (5.8)
CAD 6 (11.7)
Peripheral artery aneurysms 3 (5.8)
Hypertension 33 (64.7)
Other diseases (n, %)
Mild‑to‑moderate intellectual disability 2 (3.9)
Rheumatid arthritis 1 (1.9)
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15 (29.4  %) patients were diagnosed with TAA at mean 
age 39.9 years, however they did not meet criteria for sur-
gical correction. Six patients after first operation for AAD 
required another surgical procedure during follow-up.
In 13 patients with TAAD genetic examination was 
made to confirm/exclude the diagnosis of MFS. In 
the whole group co-existent abnormalities included: 
CoA+  BAV− 1 patient, isolated BAV− 11 patients, 
LVNC  +  ASD in one patient. Peripheral artery aneu-
rysms were present in 3 (5.8  %) patients. A history 
of stroke was present in 3 (5.8  %), CAD in 6 (11.7  %) 
patients. More than half of the all study group 33 (64.7 %) 
patients were hypertensive. Familial disease was found in 
25 (49 %) of TAAD patients. In addition, mild to moder-
ate intellectual disability was present in 2 patients (3.9 %), 
rheumatoid arthritis in 1 (1.9 %).
Mutation analysis and diagnostic sensitivity
In a total of 51 analyzed individuals we found 22 rare 
variants in a given panel of genes (Table 3). Six (27.3 %) 
of these were previously reported as pathogenic in TAAD 
patients. Among novel variants, one was a de novo event, 
and two were gene-disrupting variants. Together those 
nine variants were classified as causative. Another nine 
novel missense variants were considered likely causative 
as segregation analysis (Figs. 1, 2) either supported their 
causative effect and/or pathogenicity estimations strongly 
suggested their damaging effect. Also, in our study we 
classified as likely pathogenic a variant which was previ-
ously reported as pathogenic but was detected only in cis 
configuration with another (splice site) variant. Two mis-
sense sequence changes were considered as variants of 
unknown significance (VUS) since there was insufficient 
data for segregation study and software estimations gave 
ambiguous results. Two variants were classified as likely 
benign since they showed lack of co-segregation with the 
disease. Overall, 9 (17.6  %) of 51 probands had a posi-
tive result when considering variants classified as causa-
tive only and 18 (35.3 %) if likely causative variants were 
also included. Detailed clinical characteristics of geno-
type positive probands and family members are shown in 
Tables 4 and 5.
There were 3 recently published studies which applied 
NGS for molecular diagnosis of both syndromic and 
Table 3 Rare variants identified in our cohort and associated nomenclature, classification and database frequency
No Family Gene Nucleotide Protein Transcript Domain Classification References ExAC ESP
1 TAAD032 FBN1 c.6740‑2A>G Splice  
site
NM_000138.4 cbEGF‑like Causative This study 0 0
2 TAAD001 FBN1 c.7502_7503insA N2502* NM_000138.4 cbEGF‑like Causative This study 0 0
3 TAAD012 FBN1 c.4223G>T C1408F NM_000138.4 cbEGF‑like Causative Tiecke et al. [22] 0 0
4 TAAD080 FBN1 c.7754T>C I2585T NM_000138.4 cbEGF‑like Causative Liu et al. [48] 0 0
5 TAAD017 FBN1 c.5074_5076 
delAGA
R1692del NM_000138.4 – Causative Comeglio et al. 
[29]
0 0
6 TAAD056 FBN1 c.7916A>G Y2639C NM_000138.4 cbEGF‑like Causative Mátyás et al.  
[34]
0 0
7 TAAD038 FBN1 c.2231G>A G744E NM_000138.4 cbEGF‑like Likely causative This study 0 0
8 TAAD153 FBN1 c.2950G>A V984I NM_000138.4 TB5 Causative Grau et al. [38] 0.00005 0
9 TAAD118 TGFBR1 c.605C>T A202 V NM_004612.2 GS Likely causative This study 0 0
10 TAAD026 TGFBR1 c.844T>C Y282H NM_004612.2 Protein kinase Likely causative This study 0.00002 0




12 TAAD146 SKI c.59C>A T20 K NM_003036.3 R‑SMAD binding Causative This study 0 0
13 TAAD045 SMAD3 c.868A>T I290F NM_005902.3 MH2 Likely causative This study 0 0
14 TAAD111 ACTA2 c.80A>G D27G NM_001613.2 Actin family Likely causative This study 0 0
15 TAAD076 ACTA2 c.350A>G N117S NM_001613.2 Actin family Likely causative This study 0 0
16 TAAD024 MYH11 c.5273G>A R1758Q NP_002465.1 Coiled coil Llikely causative Zhu et al. [12] 0.0002 0.00023
17 TAAD103 MYH11 c.5499G>C E1833D NM_002474.2 Coiled coil Likely causative This study 0.0003 0.00054
18 TAAD157 COL3A1 c.2108C>T P703L NM_000090.3 Triple‑helical 
region
VUS This study 0 0
19 TAAD097 COL3A1 c.3869T>C I1290T NM_000090.3 NC1 Likely causative This study 0 0
20 TAAD130 MYLK c.608C>T P203L NM_053025.3 Ig‑like C2‑type 2 VUS This study 0 0
21 TAAD027 MYLK c.1133G>A R378H NM_053025.3 – Likely benign This study 0.0001382 0.00008
22 TAAD048 MYLK c.2069C>T T690 M NM_053025.3 Ig‑like C2‑type 5 Likely benign This study 0.000008 0.00008
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non-syndromic TAAD. Wooderchak-Donahue et al. used 
a panel of 10 genes in the group of 175 patients. Over-
all they found 51 rare variants, 10 % of patients had vari-
ants classified as pathogenic and 18 % had VUS (CNV’s 
found by SGH-array not included) [19]. Proost et al. used 
panel of 14 genes to study 55 individuals and reported 
15 causative variants and 6 VUS achieving 27 % clinical 
sensitivity [20]. Ziganshin et al. [21] used WES to study 
102 patients, of whom 72.5 % had no potentially relevant 
alterations in 21 genes analyzed. Only 4 % of participants 
Fig. 1 Pedigrees of families with fibrillinopathies
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Fig. 2 Pedigrees of families with mutations in ACTA2, COL3A1, TGFBR1, MYH11, SKI, SMAD3, TGFBR1 and TGFBR2 genes
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had variants which authors considered as deleterious 
and 22  % had previously unreported VUS. In compari-
son with the above mentioned studies the diagnostic 
yield in our study (i.e. 35.3 %) was relatively high which 
may be possibly caused by a relatively severe disease in 
our cohort (see below the section on genotype pheno-
type correlations and the data indicating that causative 
mutations are more often detected in severe disease). The 
generally low diagnostic yield (≪50 %) observed in all the 
studies indicates that in the major proportion of patients 
the disease is caused by factors (genetic or environmen-
tal) which are at present unknown.
Genotype phenotype correlations
Kaplan–Meier survival curve was constructed to com-
pare the event-free survival between probands defined 
as ‘genotype-positive’ (i.e. those with causative/likely 
causative variants) and ‘genotype-negative’ reference 
group (i.e. those without any plausible variant identi-
fied, including VUS and likely benign variants). Aortic 
events were defined as acute aortic dissection or first 
planned aortic surgery. Genotype-positive probands 
showed shorter mean event free survival (41  years, CI 
35–46) than those who were genotype-negative (51 years, 
CI 45–57, p  =  0.0083, Fig.  3). Interestingly, this effect 
Table 5 Clinical and genetic characteristics of nonsyndromic mutation carriers
AAD acute aortic dissection, Ab abdominal aorta, Ar aortic arch, As ascending aorta, AVR aortic valve replacement, BAV bicuspid aortic valve, CAD coronary artery 
disease, CVS cardiovascular system, D thoracic descending aorta, F female, HT arterial hypertension, M male, MI myocardial infarction, N normal echocardiographic 
study, NA not applicable, NE not examined, R aortic root, SC supracoronary ascending aortic replacement, SC + A supracoronary and arch prosthesis, SGI stent graft 
implantation, TAA thoracic aortic aneurysm, Y Yacoub procedure




















TAAD026 II:4‑proband F 52 AAD Surgery R, As, Ar, D, 
Ab
46 SC TGFBR1 p.Y282H
TAAD026 I:1‑father M 77 TAA 47 3.8 R, As, Ar NA NA CAD TGFBR1 p.Y282H
TAAD026 III:6‑son M 15 N 30 0.5 NA NA TGFBR1 p.Y282H
TAAD045 II:1‑proband M 47 AAD Surgery R, As, Ar, D, 
Ab
35 SC SMAD3 p.I290F
TAAD045 III:2‑son M 21 N 37 1.6 NA NA SMAD3 p.I290F
TAAD111 III:5‑
proband
M 41 AAD Surgery As, Ar, D, 
Ab
29 SC ACTA2 p.D27G
TAAD111 IV:1‑son M 19 N 31 −0.1 NA NA ACTA2 p.D27G
TAAD076 III:1‑
proband
F 29 AAD 36 2.7 R, Ad, Ab 20 SGI ACTA2 p.N117S
TAAD076 II:2‑mother F 55 N 30 0.9 NA NA ACTA2 p.N117S
TAAD076 II:3‑mat 
uncle
M 57 N 36 NE NA NA Stroke at 39 
y, MI at 
42y
ACTA2 p.N117S
TAAD024 II:3‑proband F 49 TAA Surgery As, Ar 43 SC BAV MYH11 p.R1758Q
TAAD024 III:1‑daugh‑
ter
F 24 N 30 0.6 NA NA MYH11 p.R1758Q
TAAD103 II:1‑proband M 62 TAA Surgery R, As, Ar 
onset
59 Y + AVR BAV MYH11 p.E1840D
TAAD097 II:1‑proband M 55 AAD Surgery As, Ar, D, 
Ab
40 SC + A COL3A1 p.I1290T
TAAD097 II:5‑sister F 50 TAA 44 3.4 R, As COL3A1 p.I1290T
TAAD097 III:1‑son M 33 Borderline 
TAA
42 2.0 R COL3A1 p.I1290T
TAAD097 III:4‑daugh‑
ter
F 28 N 32 1.1 COL3A1 p.I1290T
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was also found when the ‘genotype-positive’ group was 
restricted to probands with variants classified as ‘likely 
causative’: 37  years (CI 28–47) vs. 51  years (CI 45–57, 
p = 0092, Additional file 1: Figure S1). This latter obser-
vation argues that majority (if not all) of the variants clas-
sified as ‘likely pathogenic’ are functionally relevant. The 
generally faster disease progression among subjects with 
causative/likely causative variants suggests that the cur-
rently known TAAD loci are those associated with the 
most severe disease.
When we considered functional pathway altered by 
mutation, we found that the mean event free survival 
was 37  years (CI 27–47, p  =  0.0033 vs. the ‘genotype-
negative’ reference group, Additional file  1: Figure  S2) 
among the probands with defects in the TGF beta sign-
aling (i.e. those with TGFBR1, TGFBR2, SMAD3 or SKI 
mutations). The mean event free survival for probands 
with FBN1 mutations was 45  years (CI 36–53, NS vs. 
the reference), whereas for the remaining probands with 
causative/likely causative variants (i.e. those with muta-
tions in ACTA2, MYH11 or COL3A1) it was 38 years (CI 
24–52, NS vs. the reference). The particularly fast disease 
progression associated with defects in TGF beta signaling 
has been observed previously [5].
Pedigrees of families with mutations in FBN1 are 
shown in Fig. 1 and those with the remaining mutations 
in Fig. 2. Detailed clinical characteristics of genotype pos-
itive probands and their family members are presented in 
Tables 4 and 5.
FBN1
Similar to previous reports [19, 20] FBN1 variants 
were the most abundant in our study group. Among 
eight FBN1 mutations identified, 3 were novel: c.6740-
2A>G disrupting splice site acceptor, c.7502_7503insA 
(p.N2502*) introducing stop codon at exon 61, and 
p.G744E affecting calcium binding epidermal growth fac-
tor-like domain (cb EGF-like).
The proband carrying FBN1 c.6740-2A>G (family 
TAAD032) is a 21-year-old woman who was suspected of 
MFS because of TAA with Z-score of 2.6 and mild sys-
temic features with systemic score of four points. The 
proband’s mother was 53-year-old woman, with positive 
family history of AAD (her sister died at age of 31 in 6th 
month of pregnancy, and her mother died suddenly at 
age of 27 years). She had TAA with Z-score 2.7, systemic 
score of 3 points, no ocular involvement. In summary, 
without genetic examination the diagnosis of MFS would 
not be possible in the family.
p.N2502* was found in a 43-year-old patient (family 
TAAD001), suffering from AAD (Stanford, type A) at age 
of 39  years, without diagnosis of MFS, without remark-
able family history. Based on clinical features, she met 
systemic criteria (seven points) for the diagnosis of MFS. 
Family history was negative. MFS could be diagnosed on 
the basis of TAAD and systemic score, identification of 
FBN1 truncating variant confirmed the clinical diagnosis.
FBN1 p.G744E variant was identified in 22-year-old 
proband and his 48-year-old father with suspected MFS 
(family TAAD038). None of them had ectopia lentis 
or met systemic criteria for the diagnosis of MFS. The 
proband had surgical correction of pectus excavatum at 
age of 14  years, and had significant myopia (−9D). His 
major problem was prolapse of both leaflets of the mitral 
valve with significant mitral insufficiency, enlarged left 
ventricle (LVEDD 62  mm) with preserved left ventricu-
lar systolic function (LVEF 64 %). In addition dilated aor-
tic root (Z-score 3.2) was present at age of 22 years. His 
father with myopia of −3D also had mitral valve prolapse, 
however with mild mitral insufficiency and dilated aortic 
root with Z-score of 2.4. The disease is more aggressive in 
the proband than in his father.
Four of previously reported FBN1 mutations (p.C1408F, 
p.I2585T, p.R1692del, and p.Y2639C) were located in cb 
EGF-like domains, and one (p.V984I) in TGFβ Binding-
Protein-Like Domain 5 (TB5).
p.C1408F has been once reported previously [22], how-
ever, there are two more reports of another alteration in 
the same cysteine residue in MFS patients [23, 24] indi-
cating that the position may be a mutational hot spot. 
p.C1408F was found in monozygotic affected female twins 
from our study group (family TAAD012). Both twins had 
ectopia lentis, and required prophylactic aortic surgery 
due to TAA at age of 28 and 32 years. The variant is prob-
ably de novo in the family as two sisters were free of muta-
tion and parents were without any remarkable history.
Fig. 3 Kaplan–Meier analysis of event free survival in TAAD in 
probands with variants classified as causative/likely causative vs. 
those without any candidate variants identified (Log‑Rank Chi‑ square 
6.97, p = 0.0083)
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FBN1 p.I2585T first reported by Liu et  al. is one of 
the most recurrent MFS-causing mutations. According 
to the UMD-FBN1  mutations database this variant was 
detected in 30 MFS patients of either Asian or Caucasian 
descent [24–31]. We found a remarkable clinical vari-
ability in the family with six mutation carriers in three 
generations (family TAAD080). Involvement of the cardi-
ovascular system was present in the proband (AAD of the 
thoracic aorta at age of 42 years, rapidly progressive after 
emergency surgery) and in the proband’s father (no TAA, 
however aneurysm of the abdominal aorta was present 
corrected surgically at age of 60  years). Two proband’s 
sisters had only skeletal involvement with scoliosis, in 
two mutation carriers of the youngest generation we 
diagnosed potential MFS.
There are two reports of MFS patients with FBN1 
p.R1692del mutation. The first concerns a patient after 
vascular and/or valve surgery [32] and the second a 
7  years old child with ectopia lentis and minor skeletal 
and no cardiovascular involvement [29]. Larger in frame 
deletion in the same exon (5074_5097del) was reported 
in Weill-Merchesani syndrome [33]. In our family with 
two mutation carriers (family TAAD017), only proband 
42-year-old met criteria for classic MFS with both ecto-
pia lentis and TAA. His father did not have either ocular 
involvement or TAA but as he is a mutation carrier, he 
can be diagnosed as MFS genetically predisposed.
FBN1 p.Y2639C was first reported by Matyas et  al. 
[34], since then it has been found in several other stud-
ies on MFS and related disorders [25, 35, 36] including 
a report describing 19 individuals carrying p.Y2639C in 
a single family who showed extensive clinical variability 
from minor skeletal abnormalities to full diagnostic cri-
teria for MFS with TAAD and mitral valve prolapse [37]. 
In our family (TAAD056) the proband was 61 years old 
female diagnosed at age of 58 years because of a history 
of exertional dyspnea, severe aortic insufficiency with 
aortic root dilatation of 57 mm and generalized hypoki-
nesis of the left ventricle with LVEF of 46 %. She under-
went Bentall procedure which led to restoration of left 
ventricular function. Her daughter had TAA diagnosed at 
the age of 28 years with Z-score of 4.8. None of them had 
ectopia lentis or reached systemic score of seven points, 
therefore MFS could only be diagnosed based on genetic 
examination and the presence of TAA.
FBN1 p.V984I is located in so-called neonatal region 
of FBN1 where all reported mutations associated with 
neonatal MFS and the majority of point mutations asso-
ciated with atypically severe presentations were found 
[22] although it has been previously found also in a male 
patient with classical MFS [38]. Our 48-year-old female 
proband (TAAD153) has a history of Bentall proce-
dure due to severe aortic insufficiency and dilatation of 
the aortic root and ascending aorta. Interestingly, the 
proband had also tortuosity of the vessels and impaired 
healing of wounds. The diagnosis of MFS in the proband 
was possible only after genetic examination. Among the 
remaining three mutation carriers (proband’s mother and 
proband’s sons) none had TAA. Proband’s mother had 
minor skeletal involvement.
TGFBR1 and TGFBR2
We found three rare variants in genes coding TGFβ 
receptors, all located within serine threonine kinase 
domain of both proteins where the most of pathogenic 
missense variants are being found [39]. p.A527T in 
TGFBR2 has been reported previously in LDS patient 
[40]. Two novel variants in TGFBR1 (p.A202V and 
p.Y282H) we assumed to be likely causative.
TGFBR1 p.A202V was identified in 26  years old male 
with MFS diagnosed on the basis of systemic criteria and 
the presence of TAA (family TAAD118). His father died 
of AAD at age of 40 years. There was no ocular involve-
ment. The patient underwent David’s procedure at age 
of 18 years. In addition dilation of the proximal parts of 
both coronary arteries, the brachiocephalic trunk, and 
the pulmonary artery were found. At age of 6  years he 
was operated on because of horseshoe kidney.
TGFBR1 p.Y282H was identified in 52 years old female 
hypertensive patient (family TAAD026), who suffered 
from AAD type A at the age of 46  years, with chronic 
dissection of thoraco-abdominal aorta, without systemic 
features characteristic of MFS, with hyperopia (+7D). 
The variant came to her from her 77 years old father with 
TAA (aortic root 47  mm, Z-score 3.8), with coronary 
heart disease (post inferior MI), treated with CABG at 
the age of 67 years, and PCI at the age of 69 years. Her 
son is asymptomatic mutation carrier.
The proband carrying p.A527T in the TGFBR2 gene 
is a 42-year-old woman (family TAAD048) with a his-
tory of type A AAD at the age of 40 and rapid progres-
sion following emergency operation (the implantation of 
an ascending aortic prosthesis in supracoronary position) 
requiring additional two-step procedures: (Bentall opera-
tion with the aortic arch replacement and descending 
thoracic aorta replacement 9  months later). The patient 
presents few features of LDS type 1 such as hypertelorism 
and cervical spine instability, no bifid uvula and no typi-
cal signs of MFS. At the age of 17 she underwent surgery 
for branchial cleft cyst, later she required repetitive sur-
gery for recurrent umbilical hernia, lower limb varicose 
veins and hemorrhoids. She also suffers from allergic 
disease which is consistent with recently published study 
pointing to the strong predisposition to allergies among 
LDS patients due to altered TGFβ signaling [40]. MRI of 
the whole arterial tree revealed arterial tortuosity of the 
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intracranial arteries. On repetitive CT thoraco-abdom-
inal scans an aneurysm of the hepatic artery was also 
identified. The proband’s mother died at the age of 67 
subsequently to type B aortic dissection. Both proband’s 
children tested positive for TGFBR2 gene mutation. In 
the second decade of life they met systemic criteria for 
the diagnosis of MFS and had aortic root dilatation with 
Z-score 2.7 and 2.8, respectively. The proband’s brother, 
another mutation carrier, at age of 43 years had no aor-
tic root dilation and mild involvement of other tis-
sues features. At age of 41 he experienced spontaneous 
pneumothorax.
SKI
De novo SKI p.T20K mutation has been found in a 
proband with clinical suspicion of Shprintzen–Goldberg 
syndrome (family TAAD146). So far, all discovered vari-
ants causing this syndrome occurred in exon 1, between 
amino acid residues 21 and 117. Mutations in this area 
(some of them recurrent) cluster between two regions: 
one encoding R-SMAD binding domain and the other 
encoding start of Dachshund-homology domain (DHD) 
[41]. This is the first report of SGS-causing variant affect-
ing residue 20 which also is a part of R-SMAD binding 
domain emphasizing the role of this region of the gene in 
disease pathogenesis.
The 26  years old proband had TAA (aortic root size 
diameter 48.5  mm, Z-score 5.6), dilated pulmonary 
artery (31 mm), mesotelesystolic prolapse of both mitral 
leaflets with moderate mitral insufficiency, mitral ring 
of 51.4  mm, dilated left ventricle of 66  mm (LVEDD), 
dilated left atrium of 43 cm2 and LVEF of 55 % (Fig. 4). 
Systemic score for MFS was nine. Other abnormalities 
included the following: craniofacial findings (dolichoce-
phaly, downslanting palpebral features, malar flattening, 
high narrow palate with prominent palatine ridges and 
retrognathia) and skeletal findings (dolichostenomelia, 
arachnodactyly, pectus carinatum, scoliosis, pes planus, 
foot and knee malposition). Of importance, joint hyper-
mobility made it difficult for the patient to keep balance 
on the moving bus. Of the neurological anomalies mod-
erate intellectual disability was found with the patient not 
able to perform any work. Other abnormalities included 
myopia (−4/−4.5D) along with astigmatism. In addition, 
the patient suffered from recurrent hypertrophy of the 
third tonsil that restricted his breathing, operated on four 
times.
SMAD3
SMAD3 p.I290F, identified in a male proband (family 
TAAD045) with AAD at the age of 47  years is a novel 
variant located in Mad homology 2 (MH2) domain highly 
conserved among different species and other SMAD 
proteins. Neighboring variants from this locus have 
been repeatedly reported in aneurysm-osteoarthritis 
syndrome [42, 43]. The proband who had a history of 
hypertension and suffered from AAD type A at the age 
of 35 years, died of complications of dissected abdominal 
aorta at the age of 47 years. The family history was posi-
tive for heart disease (mother died at the age of 46 years, 
and brother died at the age of 26 years because of aortic 
aneurysm). One of his sons, the mutation carrier, at the 
age of 21  years presented with hypertension and mildly 
dilated aortic root with Z-score 1.6. None of the muta-
tion carriers had any history of osteoarthritis. However, 
elder of his sons, aged 23 years, free of the mutation and 
dilation of the aorta despite hypertension was operated 
on because of extraarticular, tenosynovial chondromato-
sis at age of 9 years. Furthermore his daughter, genetically 
not tested, at age of 18 years with normal aortic dimen-
sions, also had tenosynovial chondromatosis.
MYH11
The proband carrying MYH11 p.E1840D (family 
TAAD103) was 62-year-old patient with BAV, TAA and 
a history of hypertension well controlled on two drugs, 
after planned procedure of aortic mechanical valve 
implantation SJM 25  mm plus supracoronary graft at 
age of 59  years, with a history of rheumatoid arthritis. 
No PDA on angio CT scan of the aorta. The patient’s 
daughter, aged 32 years was free of aortic disease and the 
mutation-free.
The 49-year-old proband carrying MYH11 p.R1758Q 
(family TAAD1758) was diagnosed with BAV and TAA. 
At the age of 44 she underwent the supracoronary aor-
tic graft implantation. At the age of 49 she was found to 
have nonprogressive aortic arch dilatation (42 mm). One 
of her two daughters is the asymptomatic carrier of the 
mutation.
Two MYH11 mutations, identified in our probands: 
p.E1840D—a novel mutation and a previously reported 
p.R1758Q [12] are both localized in myosine tail. How-
ever, according to the previous report the p.R1758Q was 
identified only in the presence of another variant which 
resulted in skipping of exon 32 [12]. The deletion segre-
gated with disease in studied family and was predicted 
to affect myosine tail domain’s coiled-coil structure 
and the assembly of myosin thick filaments. It was not 
clear whether the additional presence of p.R1758Q in 
some affected individuals had any effect [12]. Although 
MYH11 mutations are described to cause TAA and 
PDA, families with incomplete segregation have been 
reported suggesting existence of other yet unknown 
genetic factors contributing to observed phenotypes. 
Thus, authors emphasize the need for caution during 
genetic counseling for families with MYH11 mutations 
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and patients not carrying family-specific MYH11 vari-
ant should not be excluded from further surveillance 
[44]. This might also be the case in the family TAAD103 
in which p.E1840D proband’s granddaughter was diag-
nosed with PDA while her mother was negatively tested 
for p.E1840D. However in many cases there is not 
enough data to determine if MYH11 variants (including 
p.E1840D and p.R1758Q) are sufficient to cause TAA or 
should be classified as VUS. However, considering com-
mon clinical traits (in our unrelated patients we found 
lack of PDA and the presence of bicuspid aortic valve, 
Figs. 5, 6) and relative proximity of both variants within 
coiled coil domain, we decided to classify them as likely 
pathogenic.
ACTA2
Both ACTA2 mutations detected in our cohort (p.D27G 
and p.N117S) are novel, although another change at resi-
due 117 as well as adjacent 118 have been reported in 
families with ACTA2 associated vascular diseases includ-
ing TAAD and premature CAD or stroke [45].
ACTA2 p.D27G was found in a 41  years old patient 
(family TAAD111), hypertensive, following AAD at the 
age of 29  years, operated with insertion of supracoro-
nary aortic prosthesis 29 mm, with chronic dissection of 
thoraco-abdominal aorta and positive family history for 
aggressive TAAD. Both his father and father’s sister suf-
fered from AAD and died during the corrective surgery at 
the age of 44 and 52 years, respectively. Their mother had 
Fig. 4 Cardiovascular imaging study in the patient with SKI p.T20 K variant. a 2D transthoracic echocardiography of parasternal long axis demon‑
strated aortic root aneurysm with Valsalva sinuses diameter of 48.5 mm.; b and d 2D transthoracic echocardiography in apical four chamber view 
in diastole. Enlarged left ventricle and left atrium with increased mitral annular diameter of 51.4 mm; c contrast‑enhanced, ECG‑gated CT, volume 
rendering (VR) image, the aneurysm of the ascending aorta; d color flow Doppler study revealed significant mitral regurgitation due to thickened 
and floppy mitral valve leaflets and widened mitral annulus
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planned surgery because of TAA at the age of 70 years. 
The patient did not exhibit any features of any other tis-
sue involvement, no iris flocculi. His son is a 19 years old 
asymptomatic mutation carrier.
ACTA2 p.N117S was detected in a 29-year-old female 
(family TAAD076) who suffered type B AAD at the age 
of 18 while playing tennis. Within a decade she required 
three farther corrective procedures on her thoraco-
abdominal aorta. She does not present any other tissue 
involvement. At the age of 29  years she had also TAA 
with Z-score 2.7. The proband’s mother is an asymp-
tomatic mutation carrier. She was diagnosed for mild 
arterial hypertension and hypercholesterolemia, but 
transthoracic echocardiography revealed normal aortic 
dimensions. No iris flocculi were found in the mutation 
carriers. The proband’s uncle, also mutation carrier had 
premature ischemic stroke at the age of 39  years and 
premature myocardial infarction at the age of 42. During 
the following years, he required repeated percutaneous 
coronary interventions and finally, at the age of 50 he 
underwent coronary artery by-pass grafting. On avail-
able medical records his aorta was within normal range.
COL3A1
Over 95 % of pathogenic missense variants in COL3A1 
are substitutions of glycine–amino acid essential for the 
assembly of collagen triple helix. Remaining missense 
variants are reported as benign or VUS. Same applies 
to p.P703L which in absence of any pedigree-derived 
evidence indicating its pathogenicity must be classified 
as VUS. p.I1290T however is located in noncollagen-
ous C-terminal globular (NC1) domain responsible for 
both fibril formation and cross-linking between colla-
gen molecules in the extracellular matrix [46]. At least 
one other variant in this region has been reported in 
EDS type IV [47]. Combining this data with segrega-
tion analysis and software predictions, we classified this 
variant as likely pathogenic. p.I1290T was found in a 
55  years old proband (family TAAD097), who suffered 
from Stanford type A AAD at age of 40 years, and was 
re-operated at the age of 51 because of progressive aor-
tic root dilatation with severe aortic insufficiency along 
with coronary artery bypass grafting (LIMA-LAD) due 
to CAD. His sister was diagnosed with TAA (aortic root 
Z-score 3.4), and his son at age of 33 years met border-
line criteria for the diagnosis of TAA. The proband’s 
daughter is the mutation carrier with normal aortic 
dimensions.
MYLK
Two (p.R378H and p.T690M) out of three rare missense 
variants we have found in the MYLK gene showed no 
segregation with the disease and we observed no modify-
ing effect on patients’ phenotypes so we classified them 
Fig. 5 Cardiovascular imaging study in the patient with MYH11 p.E1840D variant. a contrast‑enhanced, ECG‑gated CT, multiplanar reformatted 
image with reconstruction parallel to aortic valve shows bicuspid aortic valve in diastole; b volume rendering (VR) image, the aneurysm of the tho‑
racic aorta: root of 43 mm, ascending aorta‑ of 52 mm (maximum dimension) and aorta before the origin of brachiocephalic trunk of 40 mm, farther 
arch dimension is normal of 28 mm
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as likely benign. The third MYLK variant (p.P203L) was 
considered as VUS after considering both ambiguous 
results given by pathogenicity estimating software and 
lack of definite segregation.
Conclusions
This study broadens the spectrum of genetic background 
of thoracic aneurysms and dissections and supports its 
potential role as a prognostic factor in the patients with 
the disease.
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